CINXE.COM

<?xml version="1.0" encoding="UTF-8"?>  <rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"> <channel> <title>Bio-Techne Corporation (TECH) News</title> <link>https://investors.bio-techne.com/rss</link> <description>The latest news released by Bio-Techne Corporation (TECH)</description> <language>en-us</language> <generator>Equisolve Investor Relations Suite</generator> <image> <url>https://d1io3yog0oux5.cloudfront.net/_f0b975705403ab5250b3c1bdea3a82ff/biotechne/files/bio-techne-logo.png</url> <title>Bio-Techne Corporation (TECH) News</title> <link>https://investors.bio-techne.com/rss</link> <width>88</width> <height>31</height> </image> <item> <title>BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES</title> <link>https://investors.bio-techne.com/news/detail/456/bio-techne-announces-new-distribution-agreement-with-leader-life-sciences</link> <pubDate>Wed, 20 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/456/bio-techne-announces-new-distribution-agreement-with-leader-life-sciences</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates. Founded in 2020, Leader Life Sciences is a scientific solutions provider dedicated to empowering the research and diagnostic community in the Middle East and North Africa (MENA) region. Serving as a catalyst for innovation, they collaborate with private and public research centers, educational institutions, and healthcare facilities to bring scientific visions to life. Their expertise spans a wide range of domains, including lab automation, digital pathology, turnkey laboratory projects and diagnostics, and beyond. Under this agreement, Leader Life Sciences will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins, immunoassay kits, enzymes, small molecules, proteomic analysis instruments, and spatial biology tools to biopharma companies, laboratories, hospitals, and universities in the GCC region. "We are excited to partner with Leader Life Sciences to expand the reach of our products and services throughout the GCC countries," said Dr. Peter Schüßler, Vice President and General Manager of Bio-Techne's EMEA region. "Leader Life Sciences' extensive distribution network and industry expertise paired with Bio-Techne's innovative portfolio is the ideal combination to catalyze advances in science and medicine in the region." "We are thrilled to partner with Bio-Techne, a global leader in innovative life sciences solutions. This collaboration marks a pivotal step in our mission to empower researchers, scientists, and diagnosticians in the MENA region. Together, we are committed to providing cutting-edge technologies that accelerate discovery and enhance advancements in diagnostics, reinforcing our dedication to driving progress of the scientific community of the region," said Nirmal Kumar, Managing Director at Leader Life Sciences. For more information about Bio-Techne and its range of products and services, visit our <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">Website</a>. About Bio-Techne: Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Bio-Techne Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 Leader Life Sciences Contact: <a href="mailto:rahaf@leaderlifesciences.com" target="_blank" rel="nofollow">rahaf@leaderlifesciences.com</a> <a href="mailto:nirmal@leaderlifesciences.com" target="_blank" rel="nofollow">nirmal@leaderlifesciences.com</a> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder9541"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-announces-new-distribution-agreement-with-leader-life-sciences-302311108.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-announces-new-distribution-agreement-with-leader-life-sciences-302311108.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH</title> <link>https://investors.bio-techne.com/news/detail/455/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-research</link> <pubDate>Mon, 18 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/455/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-research</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. Running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system will enable researchers to detect the pTau217 signal in less invasive sample collection types, like plasma samples, in just 90 minutes with no manual intervention, increasing efficiency, scalability, and precision while providing the necessary data to help accelerate clinical decisions. "Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field." "As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," said Chad Holland, CEO at ALZpath. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward." About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 About ALZpath ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias. The novel ALZpath pTau217 antibody, integral to the most advanced, widely available blood-based tests to detect Alzheimer's disease, is transforming diagnosis and treatment monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. To help millions of patients in need, ALZpath democratizes access to its proprietary robust antibody, which is used by researchers, clinicians, and industry partners around the world to accelerate the discovery of new treatments and improve patient care. To learn more about the company, please visit <a href="https://alzpath.bio/" target="_blank" rel="nofollow">https://alzpath.bio/</a> and follow us on <a href="https://www.linkedin.com/company/alzpath-inc/mycompany/verification/?viewAsMember=true" target="_blank" rel="nofollow">LinkedIn</a>. Contact: Nechama Rosengarten <a href="mailto:nechama.rosengarten@finnpartners.com" target="_blank" rel="nofollow">nechama.rosengarten@finnpartners.com</a> 551-444-0784 <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder7167"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> <a href="https://mma.prnewswire.com/media/2559608/ALZpath_Logo.html" target="_blank" rel="nofollow"> <img src="https://mma.prnewswire.com/media/2559608/ALZpath_Logo.jpg" title="ALZpath" alt="ALZpath"> </a> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-research-302307463.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-research-302307463.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO</title> <link>https://investors.bio-techne.com/news/detail/454/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting-expo</link> <pubDate>Thu, 14 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/454/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting-expo</guid> <content:encoded><![CDATA[ <div class="xn-content"> Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees MINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811. "The Association for Molecular Pathology is a leading voice in the world of clinical molecular testing. We look forward to its meeting every year to discuss the latest advances in molecular diagnostics and how they can be deployed for improved laboratory outcomes," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "This year, we're excited to highlight important new products that will help labs streamline data collection and analysis in critical areas including metastatic breast cancer and carrier screening." At the AMP 2024 Annual Meeting & Expo, Asuragen will host, sponsor, or participate in a number of activities and presentations. ESR1 & Beyond: Leveraging Exosomes for Highly-Sensitive Variant Detection on qPCR This workshop will showcase the design and performance of the QuantideX® qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA + exoRNA Isolation Kit to achieve analytical sensitivity of ≤0.1% across 11 ESR1 mutations, utilizing the power of cfDNA and exosomal RNA to deliver best-in-class performance using commonly-available qPCR instruments. Speaker: Brian Haynes, PhD, Bio-Techne Diagnostics Division Date and time: Wednesday, November 20, 3:00-3:50 PM PST Location: Room 212/213 Long-Range PCR Meets Long-Read Sequencing: An Assay for 11 Hard-to-Decipher, High-Frequency Carrier Screening Associated Genes This workshop will focus on the design and performance of the AmplideX® Nanopore Carrier Plus Kit, combining AmplideX PCR chemistry with the Oxford Nanopore® platform to identify the most challenging genetic alterations like CNVs, large inversions, and pseudogenes using a consolidated workflow. Speaker: Paul A. Wadsworth, MD, PhD, Resident Physician, Pathology, Stanford University Date and time: Wednesday, November 20, 12:00-12:50 PM PST Location: Room 114/115 Fireside Chat: LDT Compliance in an Uncertain Environment With so much uncertainty around the FDA's laboratory-developed test (LDT) rule, it is challenging for laboratory leaders to make firm plans for how to achieve compliance. This session will consider three different tactical approaches for stage I of the rule: a) labs actively preparing for compliance; b) labs preparing, but cautiously using resources; and c) labs that are taking a 'wait and see' approach. Discussion Leader: Jordan Laser, MD, Asuragen Date and time: Wednesday, November 20, 5:15-6:15 PM PST Location: Room 211 POSTERS Verification of an RT-qPCR Assay System for Liquid Biopsy Surveillance of Treatment-Resistant ESR1 Mutations Presenting author: Blaine Caughron, Asuragen Poster info: G095, Genetics; Saturday, November 23, 9:15 am -10:15 am Verification of an Amplification-Based Nanopore Sequencing Assay and Software to Genotype Complex, Clinically-Relevant Variants in 11 Hard-to-Decipher Genes with High Carrier Frequencies Presenting author: Connor A. Parker, Asuragen Poster info: G094, Genetics; Friday, November 22, 9:15 am -10:15 am Freeze-Dried, Worry Thawed: Armored RNA New Lyophilized Controls Offer Potential to Advance Molecular Testing in Resource Limited Settings Presenting author: Deepa Eveleigh, Asuragen Poster info: ID046, Infectious Disease; Friday, November 22, 9:15 am -10:15 am Beta Evaluation of a Panel of 11 Challenging Genes Using ONT/AmplideX Chemistry Presenting author: Anne-Sophie Lebre, Professor of Human Genetics & Clinical Molecular Geneticist, Reims Medical School & University Hospital Poster info: G013, Genetics; Saturday, November 23, 9:15am -10:15am Stop by the Asuragen booth (#811) to learn more about the company's products for clinical laboratories. We will also be providing free, professional-quality headshots to all AMP attendees who visit our booth on Thursday or Friday. For more information about Asuragen's AMP 2024 activities, please visit <a href="https://www.bio-techne.com/about/events/association-molecular-pathology" target="_blank" rel="nofollow">https://www.bio-techne.com/about/events/association-molecular-pathology</a>. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1111"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting--expo-302305212.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-to-highlight-novel-solutions-for-cancer-and-carrier-screening-at-amp-2024-annual-meeting--expo-302305212.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS</title> <link>https://investors.bio-techne.com/news/detail/452/bio-techne-announces-ivdr-certified-hematology-controls-and-calibrators</link> <pubDate>Mon, 11 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/452/bio-techne-announces-ivdr-certified-hematology-controls-and-calibrators</guid> <content:encoded><![CDATA[<div class="xn-content"> R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices. This IVDR certification demonstrates the product's exceptional quality standards, ensuring high levels of accuracy, precision, and reliability. It marks an important milestone in Bio-Techne's commitment to meeting the needs of healthcare professionals. Hematology Controls and Calibrators are essential components in the laboratory setting that support accuracy in patient testing. With the IVDR certification, customers can be assured that Bio-Techne's R&D Systems Hematology Controls and Calibrators meet the rigorous standards required in hematology. "At Bio-Techne, we take pride in designing and manufacturing products that enable researchers and healthcare professionals to improve patients' lives. We are thrilled to be able to offer IVDR certified Hematology Controls and Calibrators to our customers, ensuring they receive the highest quality products," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow noopener">david.clair@bio-techne.com</a> 612-656-4416 <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder4192"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow noopener"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"></div> View original content to download multimedia:<a id="PRNURL" rel="nofollow noopener" href="https://www.prnewswire.com/news-releases/bio-techne-announces-ivdr-certified-hematology-controls-and-calibrators-302295034.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-announces-ivdr-certified-hematology-controls-and-calibrators-302295034.html</a> SOURCE Bio-Techne Corporation </div>]]></content:encoded> </item> <item> <title>BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES</title> <link>https://investors.bio-techne.com/news/detail/451/bio-techne-to-present-at-investor-conferences</link> <pubDate>Fri, 08 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/451/bio-techne-to-present-at-investor-conferences</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference November 12, 2024 9:30 AM PST Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM EST Stephens NASH 2024 Conference November 20, 2024 11:00 AM CST A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at <a href="https://investors.bio-techne.com/ir-calendar" target="_blank" rel="nofollow">https://investors.bio-techne.com/ir-calendar</a>. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. <div><table border="0" cellspacing="0" cellpadding="1" class="prnbcc"> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Contact: </td> <td class="prngen2" colspan="1" rowspan="1"> David Clair, Vice President, Investor Relations & Corporate Development </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> <a href="mailto:david.clair@bio-techne.com" target="_blank" class="prnews_a" rel="nofollow">david.clair@bio-techne.com</a> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> 612-656-4416 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> </td> </tr> </table></div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5076"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-to-present-at-investor-conferences-302298610.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-to-present-at-investor-conferences-302298610.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy</title> <link>https://investors.bio-techne.com/news/detail/450/scaleready-announces-multiple-g-rex-grants-have-been-awarded-to-leading-investigators-at-the-baylor-college-of-medicines-center-for-cell-and-gene-therapy</link> <pubDate>Thu, 07 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/450/scaleready-announces-multiple-g-rex-grants-have-been-awarded-to-leading-investigators-at-the-baylor-college-of-medicines-center-for-cell-and-gene-therapy</guid> <content:encoded><![CDATA[ <div class="xn-content"> ST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation and CellReady, has awarded G-Rex Grants totaling $475,000 to three leading investigators at the Baylor College of Medicine's (BCM) Center for Cell and Gene Therapy Institute (CAGT). Dr. Ann Leen, a Professor in the Department of Pediatrics at BCM's CAGT, received a $275,000 G-Rex Grant for process development and IND enabling studies related to tumor-associated neoantigen specific T cell therapies for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in pre- and post-hematopoietic stem cell (HSC) transplant. Dr. Leen has been with BCM's CAGT since 2002, is the senior or co-author on more than 100 publications, is a named inventor on 14 published patents (including several relating to G-Rex), served as the principal investigator on more than 15 clinical trials using "first in human" cell therapies, and is a co-founder of two T cell therapy companies (Allovir and Marker Therapeutics). Dr. Katie McKenna, an Assistant Professor at BCM's CAGT, received a $100,000 G-Rex Grant to develop a novel G-Rex based approach for culturing three dimensional (3D) solid tumor spheroids. Dr. McKenna's vision is to establish these 3D tumor spheroid models as a reliable representation of the tumor microenvironment (TME) compared to in vivo murine studies that traditionally accompany an Investigational New Drug (IND) application. Dr. McKenna will begin by establishing organoid models for pancreatic, breast, and lung cancer tissues before expanding to other tumor models. Dr. Dimitrios Laurin Wagner, a Tenure-Track Assistant Professor at BCM's CAGT, and Dr. Marie Pouzolles, Staff Scientist in the Wagner Lab, received a $100,000 G-Rex Grant to develop innovative gene editing platforms to create potent immune cell therapies. Specifically, the G-Rex Grant will be deployed to scale up the manufacture of non-viral gene edited T cells, leveraging their optimized non-viral CRISPR-Cas-based method for CAR insertion into specific loci of primary human T cells. Dr. Wagner received his M.D., Ph.D. from Charité Universitätsmedizin Berlin where he was the head of Research and Development at the Berlin Center for Advanced Therapies and a junior group leader at the Berlin Institutes of Health Center for Regenerative Therapies. At BCM's CAGT, Dr. Wagner and Dr. Pouzolles plan to move genome editing into the clinics to create transformative anti-cancer cell therapies. "Baylor's Center for Cell and Gene Therapy has long been at the forefront of Cell and Gene Therapy innovation and played a pivotal role in the success of G-Rex technology. G-Rex would not have become the gold standard for T cell therapy manufacturing without the input and help we received from the early adopters at Baylor. It's gratifying to know that our G-Rex Grant program will help these accomplished investigators advance their scientific objectives" said John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" target="_blank" rel="nofollow">info@scaleready.com</a>. About ScaleReady ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" rel="nofollow">info@scaleready.com</a>. About Wilson Wolf Manufacturing Wilson Wolf (<a href="http://www.wilsonwolf.com" rel="nofollow">www.wilsonwolf.com</a>) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder7467"> <a href="https://mma.prnewswire.com/media/2546864/ScaleReady_Logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2546864/ScaleReady_Logo.jpg" title="ScaleReady Logo" alt="ScaleReady Logo"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/scaleready-announces-multiple-g-rex-grants-have-been-awarded-to-leading-investigators-at-the-baylor-college-of-medicines-center-for-cell-and-gene-therapy-302297587.html" target="_blank">https://www.prnewswire.com/news-releases/scaleready-announces-multiple-g-rex-grants-have-been-awarded-to-leading-investigators-at-the-baylor-college-of-medicines-center-for-cell-and-gene-therapy-302297587.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING</title> <link>https://investors.bio-techne.com/news/detail/449/bio-techne-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting</link> <pubDate>Wed, 06 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/449/bio-techne-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Bio-Techne's spatial biology brands, <a href="https://acdbio.com/" target="_blank" rel="nofollow">Advanced Cell Diagnostics (ACD)</a> and <a href="https://lunaphore.com/" target="_blank" rel="nofollow">Lunaphore</a>, are revolutionizing spatial biology research with their pioneering innovations that are advancing the development of tailored immunotherapies to improve patient outcomes. At booth #613, ACD will present its wide range of spatial multiomics products. These products leverage the precise RNAscope™ technology and an advanced protease-free workflow for same-section RNA and protein detection assays. In combination, these capabilities empower drug discovery research, accelerate cell and gene therapy workflows, enable the characterization of key soluble factors and the immune landscape, and support the development of improved diagnostic tools for an accelerated path from translational research to clinical applications. At booth #701, Lunaphore will showcase its fully-automated, end-to-end COMET™ suite, designed to provide innovative solutions in spatial biology for the translational research community. The complete portfolio will be showcased through product demonstrations. Furthermore, attendees can test the HORIZON™ image analysis software, tailored for COMET hyperplex images, offering new features for intuitive multiomics data and neighborhood analysis. "Bio-Techne's spatial biology solutions lead the way in developing groundbreaking innovations, shaping the future of scientific discovery," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "Our mission is to empower scientists with cutting-edge technologies to accelerate research and develop the next-generation therapies. We are excited to feature our spatial portfolio at this prestigious conference." Several scientists from the company and its partners will present posters at the conference highlighting how the industry-leading capabilities of Bio-Techne's solutions enable key research and clinical applications. Bio-Techne poster presentations: Multiomic mapping of the brain: same-section, fully-automated spatial RNA and protein detection on mouse frozen tissues Friday, November 8 at 12:15 - 13:45 & 17:30 - 19:00 Presenter: Alice Comberlato, Ph.D., Lunaphore, a Bio-Techne Brand Poster number: #81 Novel fully-automated multiomics assay for profiling immune cell landscape and activation states Friday, November 8 at 12:15 - 13:45 & 17:30 - 19:00 Presenter: Anushka Dikshit, Ph.D, Advanced Cell Diagnostics, a Bio-Techne Brand Poster number: #85 Qualification of immune checkpoint biomarker antibodies in glioblastoma with multiplex immunofluorescence Friday, November 8 at 12:15 - 13:45 & 17:30 - 19:00 Presenter: Ruha Adelkar, Bio-Techne Poster number: #69 High throughput spatial mulitomic assay for assessing immune cell phenotype and function in the tumor microenvironment Saturday, November 9 at 12:15- 13:45 & 19:00 - 20:30 Presenter: Anushka Dikshit, Ph.D., Advanced Cell Diagnostics, a Bio-Techne Brand Poster number: #86 Fully automated, novel protease-free workflow for co-detection of protein-protein interaction, individual proteins and mRNA using RNAscope Multiomic LS assay Saturday, November 9 at 12:15 -13:45 & 19:10 - 20:30 Presenters: Ge-Ah Kim, Advanced Cell Diagnostics, a Bio-Techne Brand Poster number: #106 A new automated RNAscopeTM assay for the fluorescent co-detection of multiple RNA and protein biomarkers on Roche DISCOVERY ULTRA™ Saturday, November 9 at 12:15- 13:45 & 19:10 - 20:30 Presenters: Renzo Adilardi, Advanced Cell Diagnostics, a Bio-Techne Brand Poster number: #206 Poster presentations, in collaboration Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for spatial biomarker identification on immunotherapy-treated melanoma patients [research conducted in collaboration with Prof. Paolo Ascierto, National Tumor Institute Fondazione G. Pascale and Nucleai] Friday, November 8 at 12:15 - 13:45 & 17:30 - 19:00 Presenter: Ettai Markovits, Ph.D., Nucleai Poster number: #117 Enhanced analysis of tumor microenvironment and immune regulation via an automated adjustable signal amplification technique for multiplex immunofluorescence [research conducted in collaboration with Prof. Janis Taube, Johns Hopkins University School of Medicine] Saturday, November 9 at13:45 & 19:10 - 20:30 Presenter: François Rivest, Ph.D., Lunaphore, a Bio-Techne Brand Poster number: #124 About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder3229"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting-302296611.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-39th-annual-meeting-302296611.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH</title> <link>https://investors.bio-techne.com/news/detail/448/lunaphore-comet-platform-paves-the-way-for-spatial-biology-adoption-in-clinical-research</link> <pubDate>Tue, 05 Nov 2024 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/448/lunaphore-comet-platform-paves-the-way-for-spatial-biology-adoption-in-clinical-research</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for the translational research community. COMET, a best-in-class spatial biology platform, seamlessly integrates into standard clinical research workflows. Using off-the-shelf, clinically IHC-validated antibodies, new panels can be quickly developed and validated. Additionally, COMET enables high-plex workflow automation, adding unique value to clinical studies by facilitating robust and timely decision-making in treatment strategies. Research conducted in collaboration with Prof. Paolo Ascierto, National Tumor Institute Fondazione G. Pascale, and leading AI-powered spatial biomarker and diagnostics company, Nucleai, uncovered potential tumor microenvironment (TME) features predictive of response to therapy. In the cohort study of immunotherapy-treated metastatic melanoma patients, a comprehensive spatial immuno-oncology multiplex immunofluorescence (mIF) panel was combined for the first time with advanced AI-powered biomarker analysis. The findings highlight that the fully- automated workflow and AI tissue analytics can be applied more broadly in immunotherapy drug development to enhance the understanding of treatment efficacy, ultimately improving patient outcomes. "COMET enables the identification of multiple biomarkers and spatial interactions between different cell types within the TME," said Dr. Ascierto. "Its use together with Nucleai's AI spatial biomarker platform in predicting therapy response for patients enrolled in the SECOMBIT1 study, marks the first application of this innovative technology in a clinical trial, representing a significant step toward identifying predictive biomarkers." "This study demonstrates our shared vision to accelerate predictive spatial biomarker development and showcases the COMET platform's unique potential in enabling the design of more effective immunotherapy strategies in advanced cancers such as metastatic melanoma, said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "We're committed to pushing the boundaries of healthcare by advancing spatial biology in clinical research and ultimately improve patient outcomes." Another study conducted in collaboration with Prof. Janis Taube, Johns Hopkins University School of Medicine, demonstrates the potential of the novel amplification technique on the COMET platform, allowing scientists to comprehensively profile the TME, leading the way for improved insights in clinical research. At this year's Society for Immunotherapy of Cancer's (SITC) Annual Meeting novel data sets will be presented, showcasing the scientific advancements brought by COMET. To learn more about Lunaphore's poster presentations and activities at SITC, please visit: <a href="https://lunaphore.com/our-events" target="_blank" rel="nofollow">https://lunaphore.com/our-events</a> About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. About Lunaphore Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore's technology enables the identification of biomarker "signatures" with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit <a href="https://lunaphore.com/" target="_blank" rel="nofollow">https://lunaphore.com</a>. About COMET™ COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET™ enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET™ platform, please visit: <a href="https://lunaphore.com/products/comet/" target="_blank" rel="nofollow">https://lunaphore.com/products/comet/</a> Bio-Techne Corporation (NASDAQ: TECH) David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 For further information on Lunaphore: Irene Tamayo, Senior Director, Product Strategy and Marketing <a href="mailto:communications@lunaphore.com" target="_blank" rel="nofollow">communications@lunaphore.com</a> 1 An international study focusing on the different sequences of treatment in BRAF-mutated advanced melanoma patients. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1119"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/lunaphore-comet-platform-paves-the-way-for-spatial-biology-adoption-in-clinical-research-302295964.html" target="_blank">https://www.prnewswire.com/news-releases/lunaphore-comet-platform-paves-the-way-for-spatial-biology-adoption-in-clinical-research-302295964.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS</title> <link>https://investors.bio-techne.com/news/detail/447/bio-techne-releases-first-quarter-fiscal-2025-results</link> <pubDate>Wed, 30 Oct 2024 06:30:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/447/bio-techne-releases-first-quarter-fiscal-2025-results</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights <ul type="disc"> <li>First quarter organic revenue increased by 4% (5% reported) to $289.5 million. </li> <li>GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. </li> <li>Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostics & Genomics, portfolio led to 14% organic segment growth (14% reported). </li> <li>Continued uptake of our cell and gene therapy workflow solutions, including strong growth in our GMP reagent offerings.</li> </ul> The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). Adjusted diluted EPS, adjusted net earnings, adjusted gross margin, adjusted operating income, adjusted tax rate, organic growth, adjusted operating margin, earnings before interest, taxes, depreciation, and amortization (EBITDA), and adjusted EBITDA are non-GAAP measures that exclude certain items detailed later in this press release under the heading "Use of non-GAAP Adjusted Financial Measures." A reconciliation of GAAP to non-GAAP financial measures is included in this press release. "The start to fiscal 2025 was largely consistent with our expectations, as a high-level of execution by the Bio-Techne team drove continued momentum across our Diagnostics & Spatial Biology segment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "This was augmented by strong results in our cell and gene therapy business, including robust growth in our GMP reagent portfolio. The strength in cell and gene therapy, combined with favorable year-to-date funding dynamics, gives us increased confidence in the forthcoming recovery in our biotech end market." Kelderman added, "Our growth pillars, as well as our core portfolio, continue to outperform in what has proven to be a prolonged period of challenges facing the industry. The high value this novel portfolio brings to our research and clinical diagnostics customers positions the business for an even stronger future. We remain focused on delivering the solutions our customers rely on to catalyze advances in science and medicine while creating value for all our stakeholders." Bio-Techne will host an earnings conference call today, October 30, 2024 at 8:00 a.m. CDT. To listen, please dial 1-877-407-9208 or 1-201-493-6784 for international callers, and reference conference ID 13749405. The earnings call can also be accessed via webcast through the following link <a href="https://investors.bio-techne.com/ir-calendar" rel="nofollow">https://investors.bio-techne.com/ir-calendar</a>. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13749405. The replay will be available from 11:00 a.m. CDT on Wednesday, October 30, 2024, until 11:00 p.m. CST on Saturday, November 30, 2024. First Quarter Fiscal 2025 Revenue Net sales for the first quarter increased 5% to $289.5 million. Organic growth was 4% compared to the prior year, with foreign currency exchange impacting sales by approximately 1%. A business held-for-sale did not have a material impact. GAAP Earnings Results GAAP EPS was $0.21 per diluted share, versus $0.31 in the same quarter last year. GAAP operating income for the first quarter of fiscal 2025 decreased 28% to $40.0 million, compared to $55.9 million in the first quarter of fiscal 2024. GAAP operating margin was 13.8%, compared to 20.2% in the first quarter of fiscal 2024. Current year GAAP operating margin was unfavorably impacted by restructuring and restructuring-related charges. Non-GAAP Earnings Results Adjusted EPS increased to $0.42 per diluted share compared to $0.41 in the same quarter last year. Adjusted operating income for the first quarter of fiscal 2025 decreased 4% compared to the first quarter of fiscal 2024. Adjusted operating margin was 29.0%, compared to 31.4% in the first quarter of fiscal 2024. Adjusted operating margin was impacted by product mix and re-instatement of incentive compensation accruals. Segment Results Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below. Protein Sciences Segment The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment's first quarter fiscal 2025 net sales were $204.5 million, which remained flat from sales of $204.7 million for the first quarter of fiscal 2024. As of December 31, 2023, a business within the Protein Sciences Segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2025 operating results. The exclusion of first quarter of fiscal 2025 sales related to this held-for-sale business reduced sales by 1%. Organic growth for the segment was 1%, with foreign currency exchange having an immaterial impact. Protein Sciences segment's operating margin was 39.4% in the first quarter of fiscal 2025 compared to 43.2% in the first quarter of fiscal 2024. The segment's operating margin decreased primarily due to product mix and re-instatement of incentive compensation accruals. Diagnostics and Spatial Biology Segment (formerly Diagnostics and Genomics Segment) The Company's Diagnostics and Spatial Biology segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment also develops and provides spatial biology products as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Spatial Biology segment's first quarter fiscal 2025 net sales were $83.2 million, an increase of 14% from $72.8 million for the first quarter of fiscal 2024. Organic revenue growth was 14% for the first quarter of fiscal 2025, with foreign currency exchange having an immaterial impact. The Diagnostics and Spatial Biology segment's operating margin was 5.1% in the first quarter of fiscal 2025 compared to 0.7% in the first quarter of fiscal 2024. The segment's operating margin increased due to volume leverage and productivity initiatives, partially offset by re-instatement of incentive compensation accruals. Use of non-GAAP Adjusted Financial Measures: This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: <ul type="disc"> <li>Organic growth</li> <li>Adjusted diluted earnings per share</li> <li>Adjusted net earnings</li> <li>Adjusted tax rate</li> <li>Adjusted gross margin</li> <li>Adjusted operating income</li> <li>Adjusted operating margin</li> <li>Earnings before interest, taxes, depreciation, and amortization (EBITDA)</li> <li>Adjusted EBITDA</li> </ul> We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal year 2024 or fiscal year 2025. Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures. The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition. The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release. Forward Looking Statements: Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.biotechne.com. <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr> <td class="prngen2" colspan="1" rowspan="1"> Contact: </td> <td class="prngen2" colspan="1" rowspan="1"> David Clair, Vice President, Investor Relations & Corporate Development </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> David.Clair@bio-techne.com </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> 612-656-4416 </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="8" rowspan="1"> BIO-TECHNE CORPORATION CONSOLIDATED STATEMENTS OF EARNINGS (In thousands, except per share data) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net Sales </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 289,458 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 276,935 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Cost of sales </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 106,441 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 91,744 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Gross margin </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 183,017 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 185,191 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Operating Expenses: </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Selling, general and administrative </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 119,161 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 105,331 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Research and development </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 23,869 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 23,998 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total Operating Expenses </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 143,030 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 129,329 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Operating income </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 39,987 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 55,862 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other income (expense) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 184 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (6,304) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Earnings before income taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 40,171 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 49,558 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Income taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 6,571 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (1,435) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net earnings </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 33,600 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 50,993 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Earnings per share: </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Basic </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 0.21 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 0.32 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Diluted </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 0.21 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 0.31 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Weighted average common shares outstanding </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Basic </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 158,531 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 158,130 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Diluted </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 161,115 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 161,940 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="7" rowspan="1"> BIO-TECHNE CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (In thousands) (Unaudited) </td></tr> <tr> <td class="prngen3" colspan="1" rowspan="1" height="1"> </td> <td class="prngen3" colspan="1" rowspan="1" height="1"> </td> <td class="prngen3" colspan="1" rowspan="1" height="1"> </td> <td class="prngen3" colspan="1" rowspan="1" height="1"> </td> <td class="prngen3" colspan="1" rowspan="1" height="1"> </td> <td class="prngen3" colspan="1" rowspan="1" height="1"> </td> <td class="prngen3" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 6/30/2024 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> ASSETS </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Cash and equivalents </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> $ </td> <td class="prngen3" colspan="1" rowspan="1"> 187,540 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> $ </td> <td class="prngen3" colspan="1" rowspan="1"> 151,791 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Short-term available-for-sale investments </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> — </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 1,072 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Accounts receivable, net </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 223,688 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 241,394 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Inventories </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 185,041 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 179,731 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Current assets held-for-sale </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 9,459 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 9,773 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other current assets </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 42,839 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 33,658 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total current assets </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 648,567 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 617,419 </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Property and equipment, net </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 253,939 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 251,154 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Right of use assets </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 89,221 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 91,285 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Goodwill and intangible assets, net </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 1,468,589 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 1,479,744 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other assets </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 275,701 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 264,265 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total assets </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen10" colspan="1" rowspan="1"> $ </td> <td class="prngen10" colspan="1" rowspan="1"> 2,736,017 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen10" colspan="1" rowspan="1"> $ </td> <td class="prngen10" colspan="1" rowspan="1"> 2,703,867 </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> LIABILITIES AND STOCKHOLDERS' EQUITY </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Accounts payable and accrued expenses </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> $ </td> <td class="prngen3" colspan="1" rowspan="1"> 94,624 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> $ </td> <td class="prngen3" colspan="1" rowspan="1"> 112,672 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Contract liabilities </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 26,614 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 27,930 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Income taxes payable </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 3,136 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 3,706 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Operating lease liabilities - current </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 13,485 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 12,920 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other current liabilities </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 4,269 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 2,151 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total current liabilities </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 142,128 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 159,379 </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Deferred income taxes </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 50,017 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 55,863 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Long-term debt obligations </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 300,000 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 319,000 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Operating lease liabilities </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 85,433 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 87,618 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other long-term liabilities </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 19,789 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> 13,157 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stockholders' equity </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 2,138,650 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> 2,068,850 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total liabilities and stockholders' equity </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen10" colspan="1" rowspan="1"> $ </td> <td class="prngen10" colspan="1" rowspan="1"> 2,736,017 </td> <td class="prngen3" colspan="1" rowspan="1"> </td> <td class="prngen10" colspan="1" rowspan="1"> $ </td> <td class="prngen10" colspan="1" rowspan="1"> 2,703,867 </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="8" rowspan="1"> BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE (In thousands) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total consolidated net sales </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 289,458 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 276,935 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Business held-for-sale1) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 2,303 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Revenue from recurring operations </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 287,155 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 276,935 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Gross margin - GAAP </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> $ </td> <td class="prngen8" colspan="1" rowspan="1"> 183,017 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> $ </td> <td class="prngen8" colspan="1" rowspan="1"> 185,191 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Gross margin percentage - GAAP </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 63.2 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 66.9 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Identified adjustments: </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Costs recognized upon sale of acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 188 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 181 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Amortization of intangibles </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,779 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,866 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stock-based compensation, inclusive of employer taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 272 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 214 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Restructuring and restructuring-related costs </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 4,898 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Impact of business held-for-sale1) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (558) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Adjusted gross margin </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 199,596 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 197,452 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Adjusted gross margin percentage2) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 69.5 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 71.3 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr> <td class="prngen3" colspan="1" rowspan="1"> 1) </td> <td class="prngen2" colspan="1" rowspan="1"> Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> 2) </td> <td class="prngen2" colspan="1" rowspan="1"> Adjusted gross margin percentage excludes both $2,303 of revenue and $558 of gross margin for a business that has met the held-for-sale criteria. </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="8" rowspan="1"> BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE (In thousands) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total consolidated net sales </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 289,458 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 276,935 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Business held-for-sale1) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 2,303 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Revenue from recurring operations </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 287,155 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 276,935 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Operating income - GAAP </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> $ </td> <td class="prngen8" colspan="1" rowspan="1"> 39,987 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> $ </td> <td class="prngen8" colspan="1" rowspan="1"> 55,862 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Operating income percentage - GAAP </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 13.8 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 20.2 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Identified adjustments: </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Costs recognized upon sale of acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 188 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 181 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Amortization of intangibles </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 19,741 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 19,851 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Acquisition related expenses and other </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 1,513 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (588) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Certain litigation charges </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 292 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stock-based compensation, inclusive of employer taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 10,637 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,494 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Restructuring and restructuring-related costs </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,022 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 89 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Impact of business held-for-sale1) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (148) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Adjusted operating income </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 83,232 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 86,889 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Adjusted operating margin percentage2) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 29.0 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 31.4 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr> <td class="prngen3" colspan="1" rowspan="1"> 1) </td> <td class="prngen2" colspan="1" rowspan="1"> Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. </td> </tr> <tr> <td class="prngen3" colspan="1" rowspan="1"> 2) </td> <td class="prngen2" colspan="1" rowspan="1"> Adjusted operating margin percentage excludes both $2,303 of revenue and $148 of operating income for a business that has met the held-for-sale criteria. </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="8" rowspan="1"> BIO-TECHNE CORPORATION NON-GAAP ADJUSTED CONSOLIDATED NET EARNINGS and EARNINGS per SHARE (In thousands, except per share data) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="6" rowspan="1"> QUARTER </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="6" rowspan="1"> ENDED </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> <td class="prngen8" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net earnings before taxes - GAAP </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 40,171 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 49,558 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Identified adjustments: </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Costs recognized upon sale of acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 188 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 181 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Amortization of intangibles </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 19,741 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 19,851 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Amortization of Wilson Wolf intangible assets and acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 2,490 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 4,208 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Acquisition related expenses and other </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 1,674 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (442) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Certain litigation charges </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 292 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stock-based compensation, inclusive of employer taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 10,637 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,494 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Restructuring and restructuring-related costs </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,022 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 89 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Investment (gain) loss and other non-operating </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (283) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Impact of business held-for-sale1) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (148) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> <td class="prngen8" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net earnings before taxes - Adjusted </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 86,067 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 84,656 </td> <td class="prngen9" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Non-GAAP tax rate </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 21.5 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 22.0 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Non-GAAP tax expense </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> $ </td> <td class="prngen8" colspan="1" rowspan="1"> 18,536 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> $ </td> <td class="prngen8" colspan="1" rowspan="1"> 18,615 </td> <td class="prngen8" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Non-GAAP adjusted net earnings </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 67,531 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 66,041 </td> <td class="prngen9" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Earnings per share - diluted - Adjusted </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 0.42 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 0.41 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen2" colspan="1" rowspan="1"> </td></tr> <tr><td class="prngen2" colspan="1" rowspan="1"> 1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. </td></tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="8" rowspan="1"> BIO-TECHNE CORPORATION NON-GAAP adjusted tax rate (In percentages) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> GAAP effective tax rate </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 16.4 </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (2.9) </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Discrete items </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 7.2 </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 27.4 </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Long-term GAAP tax rate </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 23.6 </td> <td class="prngen12" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 24.5 </td> <td class="prngen12" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Rate impact items </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stock based compensation </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (2.8) </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (2.7) </td> <td class="prngen11" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 0.7 </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 0.2 </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Total rate impact items </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (2.1) </td> <td class="prngen12" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (2.5) </td> <td class="prngen12" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Non-GAAP adjusted tax rate </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> 21.5 </td> <td class="prngen13" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> 22.0 </td> <td class="prngen13" colspan="1" rowspan="1"> % </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="7" rowspan="1"> BIO-TECHNE CORPORATION SEGMENT REVENUE (In thousands) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Protein Sciences segment revenue </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 204,535 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 204,655 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Diagnostics and Spatial Biology segment revenue </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 83,192 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 72,797 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other revenue1) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 2,303 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> lntersegment revenue </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (572) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (517) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Consolidated revenue </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 289,458 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 276,935 </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen2" colspan="1" rowspan="1"> </td></tr> <tr><td class="prngen2" colspan="1" rowspan="1"> 1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. </td></tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="7" rowspan="1"> BIO-TECHNE CORPORATION SEGMENT OPERATING INCOME (In thousands) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Protein Sciences segment operating income </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 80,541 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 88,361 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Diagnostics and Spatial Biology segment operating income </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 4,277 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 527 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Segment operating income </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 84,818 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 88,888 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Corporate general, selling, and administrative </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (1,586) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (1,999) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Adjusted operating income </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 83,232 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 86,889 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Cost recognized upon sale of acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (188) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (181) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Amortization of intangibles </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (19,741) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (19,851) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Acquisition related expenses and other </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (1,513) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 588 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Certain litigation charges </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (292) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stock-based compensation, inclusive of employer taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (10,637) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (11,494) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Restructuring and restructuring-related costs </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (11,022) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (89) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Impact of business held-for-sale1) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 148 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Operating income </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 39,987 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 55,862 </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen2" colspan="1" rowspan="1"> </td></tr> <tr><td class="prngen2" colspan="1" rowspan="1"> 1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. </td></tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="7" rowspan="1"> BIO-TECHNE CORPORATTON RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (In thousands) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net earnings </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 33,600 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 50,993 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net interest expense (income) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 1,250 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 4,003 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Depreciation and amortization </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 28,137 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 28,540 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Income taxes </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 6,571 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (1,435) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> EBITDA </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 69,558 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 82,101 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Costs recognized upon sale of acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 188 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 181 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Amortization of Wilson Wolf intangible assets and acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 2,490 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 4,208 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Acquisition related expenses and other </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 1,674 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (442) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Certain litigation charges </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 292 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stock-based compensation, inclusive of employer taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 10,637 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,494 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Restructuring and restructuring-related costs </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 11,022 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 89 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Investment (gain) loss and other non-operating </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (283) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Impact of business held-for-sale1) </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (148) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Adjusted EBITDA </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 95,713 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 97,348 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen2" colspan="1" rowspan="1"> </td></tr> <tr><td class="prngen2" colspan="1" rowspan="1"> 1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. </td></tr> </table></div> <div><table border="0" cellspacing="0" cellpadding="0" class="prnbcc"> <tr><td class="prngen4" colspan="7" rowspan="1"> BIO-TECHNE CORPORATION CONDENSED CASH FLOW (In thousands) (Unaudited) </td></tr> <tr> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> <td class="prngen5" colspan="1" rowspan="1" height="1"> </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen4" colspan="5" rowspan="1"> QUARTER </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen6" colspan="5" rowspan="1"> ENDED </td> </tr> <tr> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2024 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="2" rowspan="1"> 9/30/2023 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> CASH FLOWS FROM OPERATING ACTIVITIES </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net earnings </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 33,600 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> $ </td> <td class="prngen5" colspan="1" rowspan="1"> 50,993 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Adjustments to reconcile net earnings to net cash provided by operating activities </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Depreciation and amortization </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 28,137 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 28,540 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Costs recognized on sale of acquired inventory </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 188 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 181 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Deferred income taxes </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (5,340) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (11,591) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Stock-based compensation expense </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 10,184 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 10,093 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Fair value adjustment to available-for-sale investments </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (283) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> (Gain) Loss on equity method investment </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (374) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 2,382 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Asset impairment restructuring </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 6,039 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Fair value adjustment to contingent consideration payable </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (1,750) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Other operating activities </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (8,545) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (19,182) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net cash provided by (used in) operating activities </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 63,889 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 59,383 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> CASH FLOWS FROM INVESTING ACTIVITIES </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Proceeds from sale of available-for-sale investments </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 1,085 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 23,759 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Additions to property and equipment </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (9,172) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (13,592) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Acquisitions, net of cash acquired </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> — </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (166,426) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Distributions from (Investments in) Wilson Wolf </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 1,403 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 2,149 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Investment in Spear Bio </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (15,000) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> — </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net cash provided by (used in) investing activities </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (21,684) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (154,110) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> CASH FLOWS FROM FINANCING ACTIVITIES </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Cash dividends </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (12,688) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (12,654) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Proceeds from stock option exercises </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 25,101 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 14,394 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Long-term debt activity, net </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (19,000) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 90,000 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Taxes paid on RSUs and net share settlements </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (4,984) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (20,228) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net cash provided by (used in) financing activities </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (11,571) </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 71,512 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Effect of exchange rate changes on cash and cash equivalents </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 5,115 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen7" colspan="1" rowspan="1"> (8,693) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Net increase (decrease) in cash and cash equivalents </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> 35,749 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen3" colspan="1" rowspan="1"> (31,908) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Cash and cash equivalents at beginning of period </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 151,791 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> </td> <td class="prngen8" colspan="1" rowspan="1"> 180,571 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Cash and cash equivalents at end of period </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 187,540 </td> <td class="prngen5" colspan="1" rowspan="1"> </td> <td class="prngen9" colspan="1" rowspan="1"> $ </td> <td class="prngen9" colspan="1" rowspan="1"> 148,663 </td> </tr> </table></div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2277"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-releases-first-quarter-fiscal-2025-results-302290915.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-releases-first-quarter-fiscal-2025-results-302290915.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE DECLARES DIVIDEND</title> <link>https://investors.bio-techne.com/news/detail/446/bio-techne-declares-dividend</link> <pubDate>Wed, 30 Oct 2024 06:30:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/446/bio-techne-declares-dividend</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be payable November 22, 2024, to all common shareholders of record on November 11, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio techne.com. Forward Looking Statements: Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. <div><table border="0" cellspacing="0" cellpadding="1" class="prnbcc"> <tr> <td class="prngen2" colspan="1" rowspan="1"> Contact: </td> <td class="prngen2" colspan="1" rowspan="1"> David Clair, Vice President, Investor Relations & Corporate Development </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> <a href="mailto:David.Clair@bio-techne.com" target="_blank" class="prnews_a" rel="nofollow">David.Clair@bio-techne.com</a> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> 612-656-4416 </td> </tr> </table></div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1119"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302290718.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302290718.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics</title> <link>https://investors.bio-techne.com/news/detail/445/scaleready-announces-a-g-rex-grant-has-been-awarded-to-luminary-therapeutics</link> <pubDate>Tue, 29 Oct 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/445/scaleready-announces-a-g-rex-grant-has-been-awarded-to-luminary-therapeutics</guid> <content:encoded><![CDATA[ <div class="xn-content"> ST. PAUL, Minn., Oct. 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation (NASDAQ: TECH), today announced that Luminary Therapeutics has been awarded a $300,000 G-Rex® Grant. Luminary's G-Rex® Grant will enable expeditious process development and IND-enabling studies of several novel CAR γδ T cell therapies that will be evaluated in Phase 1 clinical trials for the treatment of various autoimmune conditions. Luminary Therapeutics' CAR γδ T cell drug products contain a combination of the Vδ1 and Vδ2 subsets, a distinct approach from other developers of γδ T cell therapies, which Luminary anticipates providing improved cytotoxicity, greater adaptive capacity, and increased persistence. Luminary's technology also employs an "immune cloaking" mechanism to assist the γδ T cells in evading the host's immune system by reducing the expression of MHC class I/II on the surface of the γδ T cells. Finally, Luminary Therapeutics deploys Bio-Techne's novel transposition-based gene engineering technology called TcBuster™ which has fundamental advantages in the reduction of time and cost associated with clinical translation of a cell therapy drug product. Luminary has previously presented cost analysis indicating that their CAR γδ T cell therapies can yield 180-200 patient doses per manufacturing run at a manufacturing cost of less than $10,000 per drug product. "Luminary is very grateful to be a beneficiary of the G-Rex Grant Program. The G-Rex Grant Program is a very creative, non-dilutive funding mechanism that aligns the interest of all stakeholders. It will directly impact our ability to generate the clinically significant data we need to attract the investment required to advance the state of our γδ T cell pipeline," says Mr. Jeff Liter, CEO of Luminary Therapeutics. "We're happy to support Luminary Therapeutics with a G-Rex Grant. The program will accelerate the clinical use of Luminary's γδ T cell therapy program and this is yet another example of how the G-Rex Grant Program is saving time and money for recipients," said John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of G-Rex. As part of the G-Rex Grant, Luminary will optimize several CAR γδ T cell therapies to enhance the resiliency, safety, and function of their CAR by incorporating safety switches, novel co-stimulatory domains, endogenous growth factor production, and MHC-I/II inhibitory elements. Large-scale, cGMP-compliant manufacturing will occur to support multiple Investigational New Drug (IND) applications that are estimated to be filed with the Food and Drug Administration (FDA) for the initiation of several Phase 1 clinical trials to evaluate the safety and efficacy of the several CAR γδ T cell therapies in a suite of autoimmune diseases. ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" target="_blank" rel="nofollow">info@scaleready.com</a>. About Luminary Therapeutics Luminary Therapeutics is revolutionizing allogeneic CAR-T therapy by pioneering a triple receptor CAR design aimed at surpassing the efficacy of conventional single receptor CD19 treatments for autoimmune diseases. Additionally, our innovative split co-stimulatory CAR design is poised to propel the industry forward in addressing solid tumors. Currently, Luminary is conducting three Phase I First-in-Human trials utilizing an autologous format to establish safety and detect early indications of efficacy. Encouragingly, our second treated patient has already achieved a complete response (CR) without experiencing cytokine release syndrome (CRS). As we embark on the early stages of a Series A fundraising round, Luminary is committed to advancing our assets through the clinical trial pipeline, bringing hope and transformative therapies to patients in need. About ScaleReady ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" rel="nofollow">info@scaleready.com</a>. About Wilson Wolf Manufacturing Wilson Wolf (<a href="http://www.wilsonwolf.com" rel="nofollow">www.wilsonwolf.com</a>) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5633"> <a href="https://mma.prnewswire.com/media/2541888/ScaleReady_Logo_RGB__2___002.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2541888/ScaleReady_Logo_RGB__2___002.jpg" title="ScaleReady Logo" alt="ScaleReady Logo"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-luminary-therapeutics-302289750.html" target="_blank">https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-luminary-therapeutics-302289750.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 30, 2024, TO ANNOUNCE FIRST QUARTER FISCAL 2025 FINANCIAL RESULTS</title> <link>https://investors.bio-techne.com/news/detail/444/bio-techne-to-host-conference-call-on-october-30-2024-to-announce-first-quarter-fiscal-2025-financial-results</link> <pubDate>Thu, 10 Oct 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/444/bio-techne-to-host-conference-call-on-october-30-2024-to-announce-first-quarter-fiscal-2025-financial-results</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results. Access to the discussion may be obtained as follows: <div><table border="0" cellspacing="0" cellpadding="1" class="prnbcc"> <tr> <td class="prngen2" colspan="1" rowspan="1"> Time: </td> <td class="prngen2" colspan="1" rowspan="1"> 8:00 a.m. CDT </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Date: </td> <td class="prngen2" colspan="1" rowspan="1"> October 30, 2024 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Dial-in: </td> <td class="prngen2" colspan="1" rowspan="1"> 1-877-407-9208 or 1-201-493-6784 (for international callers) </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Conference ID: </td> <td class="prngen2" colspan="1" rowspan="1"> 13749405 </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> Webcast: </td> <td class="prngen2" colspan="1" rowspan="1"> <a href="https://investors.bio-techne.com/ir-calendar" target="_blank" class="prnews_a" rel="nofollow">https://investors.bio-techne.com/ir-calendar</a> </td> </tr> </table></div> A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13749405. The replay will be available from 11:00 a.m. CDT on Wednesday, October 30, 2024, until 11:00 p.m. CST on Saturday, November 30, 2024. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. <div><table border="0" cellspacing="0" cellpadding="1" class="prnbcc"> <tr> <td class="prngen2" colspan="1" rowspan="1"> Contact: </td> <td class="prngen2" colspan="1" rowspan="1"> David Clair, Vice President, Investor Relations & Corporate Development </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> <a href="mailto:david.clair@bio-techne.com" target="_blank" class="prnews_a" rel="nofollow">david.clair@bio-techne.com</a> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> 612-656-4416 </td> </tr> </table></div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5444"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-october-30-2024-to-announce-first-quarter-fiscal-2025-financial-results-302271430.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-october-30-2024-to-announce-first-quarter-fiscal-2025-financial-results-302271430.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences</title> <link>https://investors.bio-techne.com/news/detail/443/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences</link> <pubDate>Wed, 09 Oct 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/443/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences</guid> <content:encoded><![CDATA[ <div class="xn-content"> <ul type="disc"><li>Award will support clinical manufacturing of the Company's promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform</li></ul> ST. PAUL, Minn., Oct. 9, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, and LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company about to start clinical trials for its first-in-class allogeneic innate cell therapy, today announced that LIfT Biosciences has been awarded a $300,000 G-Rex® Grant to establish clinical manufacturing of its promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform. John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex, said: "We're eager to use our expertise to quickly create a highly efficient and scalable G-Rex manufacturing platform that will allow LIfT Biosciences to assess the potential of N-LIfT to penetrate the solid tumor microenvironment, kill cancer cells, and simultaneously recruit the patient's endogenous immune system." Andrew Willis, Chief Development and Regulatory Officer at LIfT Biosciences, said: "Once infused, N-LIfT produces a new type of myeloid cell called an Immunomodulatory Alpha Neutrophil (IMAN) which is an enhanced neutrophil that is designed to overcome treatment resistance in solid tumours. IMANs can identify solid tumors irrespective of antigen and kill them both directly and indirectly via recruiting the patient's own cancer killing immune cells into the tumour site. We've selected G-Rex as our clinical manufacturing platform and associated expertise that comes with it to expedite our path to patient treatment." As part of the G-Rex Grant, LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for scale out to late stage clinicals and beyond. ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About LIfT BioSciences LIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class alpha neutrophil cell therapy that overcomes treatment resistance in solid tumours. LIfT's Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner, and turn the tumour microenvironment against the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered CAR IMAN cell therapies to destroy a range of solid tumours. See <a href="https://www.liftbiosciences.com/" target="_blank" rel="nofollow">www.LIfTbiosciences.com</a> Contact: ICR Consilium Lindsey Neville, Namrata Taak <a href="mailto:liftbiosciences@consilium-comms.com" target="_blank" rel="nofollow">liftbiosciences@consilium-comms.com</a> About ScaleReady ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" target="_blank" rel="nofollow">info@scaleready.com</a>. About Wilson Wolf Manufacturing Wilson Wolf (<a href="http://www.wilsonwolf.com" rel="nofollow">www.wilsonwolf.com</a>) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder6762"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences-302271064.html" target="_blank">https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences-302271064.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>ScaleReady announces a G-Rex® Grant has been awarded to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute</title> <link>https://investors.bio-techne.com/news/detail/442/scaleready-announces-a-g-rex-grant-has-been-awarded-to-dr-eric-tran-of-the-earle-a-chiles-research-institute-a-division-of-providence-cancer-institute</link> <pubDate>Tue, 08 Oct 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/442/scaleready-announces-a-g-rex-grant-has-been-awarded-to-dr-eric-tran-of-the-earle-a-chiles-research-institute-a-division-of-providence-cancer-institute</guid> <content:encoded><![CDATA[ <div class="xn-content"> ST. PAUL, Minn., Oct. 8, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Eric Tran, Ph.D, Associate Member of the Earle A. Chiles Research Institute, a division of the Providence Cancer Institute, has been awarded a G-Rex Grant. Dr. Tran's $200,000 G-Rex Grant will enable process development and IND enabling studies of a novel KRAS-targeted TCR-T cell therapy. "We have utilized G-Rex devices for a long time for our adoptive cell therapy efforts. This G-Rex Grant will substantially defray the costs associated with bringing our next generation TCR-T cell therapy into the clinic and advance the state of our manufacturing," said Dr. Tran "Dr. Tran has been contributing to the field of cell and gene therapy for nearly 15 years and we are grateful for the opportunity to award a G-Rex Grant to Dr. Tran and the Providence Cancer Institute. Providence's G-Rex Grant will help expedite an IND application of their novel KRAS-targeted TCR T-cell therapy to treat a variety of solid tumors in a Phase 1/1b clinical trial," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of the G-Rex Grant, Dr. Tran plans to optimize their manufacturing process by reducing the process duration and implementing fully-closed system G-Rex bioreactors. Dr. Tran will make use of Bio-Techne's new GMP cytokines that have been right-sized for one-touch G-Rex close process manufacturing, setting the stage for simple and efficient scale out. ScaleReady's G-Rex® Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About ScaleReady ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" target="_blank" rel="nofollow">info@scaleready.com</a>. About Wilson Wolf Manufacturing Wilson Wolf (<a href="http://www.wilsonwolf.com" rel="nofollow">www.wilsonwolf.com</a>) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Providence Cancer Institute of Oregon Providence Cancer Institute of Oregon, a part of Providence St. Joseph Health, offers the latest in cancer services, including diagnosis, treatment, prevention, education and support. Providence is home to the Earle A. Chiles Research Institute, an internationally renowned leader in the field of cancer immunotherapy since 1993, where investigators lead numerous clinical trials for patients with cancers of the breast, colon, prostate, lung, esophagus, liver, pancreas, head and neck, ovary, skin, blood and other conditions. Learn more at <a href="https://www.globenewswire.com/Tracker?data=dXH-v_H5Ky7FW4tL6JKO7YNWUGgcd-McgKdfwUsAR0MBEdEDHcvVVv8WPbjmvE2I-_UpSQyqMZdQeLOghHCSECnNIXWx3heFSYujdbjGslNMkloBqcYgHTT0DvvWXgrEJb3PxH1sHatVpBVifBeaQQ==" target="_blank" rel="nofollow">Providence.org/ORcancer</a>. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder5034"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-dr-eric-tran-of-the-earle-a-chiles-research-institute-a-division-of-providence-cancer-institute-302269620.html" target="_blank">https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-dr-eric-tran-of-the-earle-a-chiles-research-institute-a-division-of-providence-cancer-institute-302269620.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>ScaleReady announces a G-Rex® Grant has been awarded to renowned cancer immunologist Dr. Christopher A. Klebanoff</title> <link>https://investors.bio-techne.com/news/detail/441/scaleready-announces-a-g-rex-grant-has-been-awarded-to-renowned-cancer-immunologist-dr-christopher-a-klebanoff</link> <pubDate>Mon, 07 Oct 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/441/scaleready-announces-a-g-rex-grant-has-been-awarded-to-renowned-cancer-immunologist-dr-christopher-a-klebanoff</guid> <content:encoded><![CDATA[ <div class="xn-content"> ST. PAUL, Minn., Oct. 7, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Christopher A. Klebanoff, MD, a physician-scientist at Memorial Sloan Kettering Cancer Center (MSK) has been awarded a G-Rex® Grant. Dr. Klebanoff's $300,000 G-Rex® Grant will provide enabling reagents to facilitate process development, IND-enabling studies, and support clinical manufacturing of a novel CD8α/β-armored TCR-T cell therapy targeting an HLA-A*11:01-restricted RAS (G12D) public neoantigen in a Phase 1 clinical trial. "Dr. Klebanoff is a leader in the field with over 20 years of experience, and we are fortunate to be able to support his novel approach to cancer treatment. We are confident that this G-Rex Grant will significantly accelerate the path to clinical results and simultaneously set the stage for highly efficient closed system scale out. We are also hopeful that patients will receive significant benefit from treatment with armored TCR-T drug products," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. "Our armored TCR-T therapy is designed to recognize antigen targets that are specific to every cancer cell. We are diligently working to bring this public neoantigen cellular immunotherapy into the clinic to assess its safety and potential efficacy against common solid cancers with significant unmet medical need. The G-Rex Grant will expedite development and accelerate our entrance into human clinical trials," said Dr. Klebanoff, who serves as an Attending Physician, Laboratory Head, Human Oncology & Pathogenesis Program, and Member Investigator, Center for Cell Engineering at MSK. Dr. Klebanoff is also a Scientific Co-Founder of Affini-T Therapeutics, and a member of the Parker Institute for Cancer Immunotherapy (PICI). As part of the G-Rex Grant, Dr. Klebanoff and Dr. Chandran at MSK plan to complete their pre-clinical process development which will include the incorporation of Wilson Wolf's fully closed-system G-Rex bioreactors and the GatheRex for semi-automated volume reduction, cell concentration, and harvest. Additionally, Dr. Klebanoff expects to perform a technology transfer to MSK's cGMP facility, which will perform engineering runs in support of an Investigational New Drug (IND) application to be filed with the FDA with the hope of initiating a Phase 1 clinical trial. "Our goal is to thoughtfully develop and expeditiously transfer a robust manufacturing framework that will reliably and reproducibly enable the generation of infusion products for cancer patients by our cGMP facility. Our hope is that this public-neoantigen specific TCR-T therapy will benefit a patient population that currently does not have many treatment options available. We also recognize this as an invaluable opportunity to holistically learn from this bench-to-bedside experience as we continue to discover and innovate in the lab.", said Smita S. Chandran, PhD, a Scientific Research Lead in the Klebanoff Lab at MSK, who led the discovery and development of the HLA-A*11/RAS(G12D) TCR-T therapeutic. The G-Rex Grant will also support clinical manufacturing runs of their autologous TCR-T cell therapy. Expedited patient enrollment is expected to occur because of MSK's unique IMPACT Program, that prescreens (via next generation sequencing) all incoming patients for commonly mutated genes. MSK will also get early access to a new line of closed system GMP reagents from Bio-Techne that are tailor-made for use with fully-closed system G-Rex bioreactors. The G-Rex ProPak™ CAR-TCR Cytokine Kits, estimated to be commercially available later this year, are weldable bags of liquid cytokines and are designed to streamline reagent preparation and administration in a GMP manufacturing setting without the use of a biosafety cabinet (BSC). ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About ScaleReady ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" target="_blank" rel="nofollow">info@scaleready.com</a>. About Wilson Wolf Manufacturing Wilson Wolf (<a href="http://www.wilsonwolf.com" rel="nofollow">www.wilsonwolf.com</a>) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex process at a time. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder3998"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-renowned-cancer-immunologist-dr-christopher-a-klebanoff-302268476.html" target="_blank">https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-renowned-cancer-immunologist-dr-christopher-a-klebanoff-302268476.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH</title> <link>https://investors.bio-techne.com/news/detail/440/lunaphore-partners-with-discovery-life-sciences-to-bring-innovative-spatial-biology-solutions-to-clinical-research</link> <pubDate>Thu, 26 Sep 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/440/lunaphore-partners-with-discovery-life-sciences-to-bring-innovative-spatial-biology-solutions-to-clinical-research</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, <a href="https://lunaphore.com/" target="_blank" rel="nofollow">Lunaphore</a>, is partnering with <a href="https://dls.com/" target="_blank" rel="nofollow">Discovery Life Sciences (Discovery)</a> to add Lunaphore <a href="https://lunaphore.com/products/comet/" target="_blank" rel="nofollow">COMET™</a>, a best-in-class spatial biology platform, to Discovery's global suite of biospecimen products and specialty lab services supporting customers with clinical research. The strategic partnership leverages Lunaphore's COMET technology, the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities, with Discovery's scientific expertise to advance immuno-oncology, immunology, neuroscience, and infectious disease research across all development stages at a new level of precision and speed. Discovery's <a href="https://dls.com/biomarker-services/molecular-pathology/lunaphore-comet-hyperplex-if-services/" target="_blank" rel="nofollow">Lunaphore COMET Hyperplex Immunofluorescence Services</a> will facilitate the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights to advance biomarker discovery, patient stratification, and translational medicine. "We are excited to expand our specialty lab services offering to include Lunaphore COMET Hyperplex Immunofluorescence Services," said Discovery CEO Greg Herrema. "By integrating COMET with Discovery's molecular pathology expertise, this partnership is poised to drive biomedical research breakthroughs. This new service combined with our rigorous regulatory compliance processes will provide pharmaceutical companies with the ability to develop Clinical Laboratory Improvement Amendment (CLIA) compliant hyperplex tests." "Discovery Life Sciences stands out as a pioneering global leader offering COMET's cutting-edge capabilities to biopharmaceutical clients across the U.S., Europe, and APAC," said Matt McManus, President of Bio-Techne's Diagnostics & Genomics Segment. "This strategic partnership furthers Bio-Techne's commitment to push the boundaries of research to transform patient care. I look forward to seeing COMET accelerate the adoption of spatial biology techniques in clinical trials." About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. <div><table border="0" cellspacing="0" cellpadding="1" class="prnbcc"> <tr> <td class="prngen2" colspan="1" rowspan="1"> Contact: </td> <td class="prngen2" colspan="1" rowspan="1"> David Clair, Vice President, Investor Relations & Corporate Development </td> <td class="prngen2" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> <a href="mailto:david.clair@bio-techne.com" target="_blank" class="prnews_a" rel="nofollow">david.clair@bio-techne.com </a> </td> <td class="prngen2" colspan="1" rowspan="1"> </td> </tr> <tr> <td class="prngen2" colspan="1" rowspan="1"> </td> <td class="prngen2" colspan="1" rowspan="1"> 612-656-4416 </td> <td class="prngen2" colspan="1" rowspan="1"> </td> </tr> </table></div> About Lunaphore Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore's technology enables the identification of biomarker signatures with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit <a href="https://lunaphore.com/" target="_blank" rel="nofollow">https://lunaphore.com</a>. About COMET™ Lunaphore COMET™ is the only fully-automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. The multiomics capability of COMET enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. To learn more about the COMET platform, please visit: <a href="https://lunaphore.com/products/comet/" target="_blank" rel="nofollow">https://lunaphore.com/products/comet/</a> About Discovery Life Sciences Discovery Life Sciences is a leading global provider of biospecimen products and specialty lab services. The company enables the discovery and development of therapies and diagnostics by providing pharmaceutical, biotech, and diagnostic companies with the highest quality biospecimens, in vitro preclinical solutions, and cell and gene therapy starting materials. Additionally, Discovery offers a complete suite of specialty lab services, including genomics, proteomics, molecular pathology, and cell biology, to support both prospective and retrospective clinical trials. For more information, visit <a href="https://dls.com/" target="_blank" rel="nofollow">dls.com</a>. For further information on Lunaphore: Lindsey Rodger, Head of Communications <a href="mailto:communications@lunaphore.com" target="_blank" rel="nofollow">communications@lunaphore.com</a> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder4352"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/lunaphore-partners-with-discovery-life-sciences-to-bring-innovative-spatial-biology-solutions-to-clinical-research-302258200.html" target="_blank">https://www.prnewswire.com/news-releases/lunaphore-partners-with-discovery-life-sciences-to-bring-innovative-spatial-biology-solutions-to-clinical-research-302258200.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING</title> <link>https://investors.bio-techne.com/news/detail/439/bio-techne-to-present-at-neuroscience-2024-the-society-for-neuroscience-sfn-annual-meeting</link> <pubDate>Tue, 24 Sep 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/439/bio-techne-to-present-at-neuroscience-2024-the-society-for-neuroscience-sfn-annual-meeting</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024, in Chicago, Illinois. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"> <img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"> </a> </div> At booth #1165, Bio-Techne will feature its market-leading portfolio of high-quality life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions. These technologies are accelerating research by streamlining biomarker discovery and quantification, optimizing neural cell cultures and organoid models, and transforming drug discovery and screening processes. In a nanosymposium, Bio-Techne will discuss a study investigating senescence in the aging brain, highlighting the novel RNAscope™ Multiomic LS assay for high-throughput spatial analysis. Additionally, the team will present a poster detailing Bio-Techne's commitment to antibody validation for use on COMETTM, the fully automated, high-throughput, hyperplex spatial biology platform from LunaphoreTM, a Bio-Techne brand. Bio-Techne will also host a Product Theater presentation in collaboration with FUJIFILM Cellular Dynamics, Inc. The presentation will focus on intracellular signaling in Alzheimer's disease, including the use of Simple Western™ automated western technology for protein size characterization and quantification directly in complex samples like cell and tissue lysates. This technology will be further highlighted in a poster presentation from Cell Signaling Technology, demonstrating its use in characterizing iPSC-derived microglial activation. "We are proud to support the advancement of neuroscience research with our portfolio of innovative proteomic research tools, research reagents, and spatial biology solutions," said Kim Kelderman, Bio-Techne's President and Chief Executive Officer. "Scientists rely on our suite of cutting-edge solutions to further the understanding of neuroscience and other biological processes, enabling the development of next-generation therapies and treatments. We are looking forward to showcasing our solutions at this important conference." To learn more about Bio-Techne's activities at Neuroscience 2024, visit <a href="https://www.bio-techne.com/about/events/SfN" target="_blank" rel="nofollow">https://www.bio-techne.com/about/events/SfN</a>. Bio-Techne Speaker Presentations: Simple Western™ Capillary Immunoassays: A Game Changer in Elucidating Intracellular Signaling in Alzheimer's Disease Monday, October 7 at 2:30pm Presenters: Scott Schachtele, PhD, Product Manager, Neuroscience, FUJIFILM Cellular Dynamics Charles Haitjema, Senior Research Area Manager, Analytical Solutions Division, Bio-Techne Location: Exhibit Hall, Aisle 900, Product Theater 1 Investigating Hallmarks of Senescence in the Aging Brain Using a Novel RNA-Protein Multiomic Co-Detection Assay Wednesday, October 9, 3:00pm - 3:15pm Presenter: Debia Wakhloo, PhD, Application Scientist, Marketing Location: MCP Room S106 Bio-Techne Poster Presentations: An Automated Assay for Precise and Sensitive Quantification of pTau217 in Plasma and Cerebrospinal Fluid Sunday, October 6, 3:00pm – 4:00pm Presenter: Yoav Noam, PhD, Senior Manager, Research & Development Poster Session: LBA003 – Theme C, Late Breaking Posters Abstract: 13849 Bridging the Gap in Synaptic Research: Visualizing Neurexin and Neuroligin Interactions Using Multiomic RNAscope Technology Sunday, October 6, 1:00pm – 2:00pm Presenter: Debia Wakhloo, PhD, Application Scientist, Marketing Poster Session: PSTR143 – Biochemical and Molecular Technologies I Abstract: 5821 Spatial Multiomic Assay for Studying Interneuron Heterogeneity in the Brain Tuesday, October 8, 3:00pm – 4:00pm Presenter: Anushka Dikshit, PhD, Senior Manager, Applications Poster Session: LBA009 – Theme I, Late Breaking Posters Abstract: 13972 Evaluation of IDH1, EGFR, IGF1R and Ki67 Biomarkers in Glioblastoma using Lunaphore COMET™ Platform Wednesday, October 9, 2:00pm - 3:00pm Presenter: Alexander Kalyuzhny, PhD, Sr. Manager, Antibody Validation Poster Session: PSTR444 - Glioblastoma and Other Nervous System Cancers: Mechanisms and Techniques Abstract: 10867 Poster Presentation, In Collaboration: Characterization of iPSC-Derived Human Microglial Activation Using Automated, Multiplex Capillary Western Blot Analysis Sunday, October 6, 10:00am - 11:00am Presenter: Richard Cho, PhD, Associate Director, Neuroscience, Cell Signaling Technology Poster Session: PSTR058 - In Vitro Modeling of Neuroinflammation and Neurodegeneration Abstract: 8455 About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="http://www.bio-techne.com/" target="_blank" rel="nofollow">http://www.bio-techne.com</a> or follow the Company on social media at <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. <a href="https://investors.bio-techne.com/company-information" target="_blank" rel="nofollow">About Bio-Techne Corporation</a> (NASDAQ: TECH) Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-to-present-at-neuroscience-2024the-society-for-neuroscience-sfn-annual-meeting-302244769.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-to-present-at-neuroscience-2024the-society-for-neuroscience-sfn-annual-meeting-302244769.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape</title> <link>https://investors.bio-techne.com/news/detail/438/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape</link> <pubDate>Wed, 18 Sep 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/438/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape</guid> <content:encoded><![CDATA[ <div class="xn-content"> ST. PAUL, Minn., Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has been awarded a G-Rex® Grant. ImmunoScape's $250,000 G-Rex® Grant will enable process development and IND enabling studies of their novel WT1-targeted TCR-T cell therapy. "We are thankful for ScaleReady's G-Rex Grant Program and are grateful to receive an award that will substantially defray the time and cost of bringing our novel therapy into the clinic," said Dr. Tania Ribeiro, Senior Director and Head of CMC. "We are proud to award ImmunoScape a G-Rex Grant to facilitate the clinical readiness of their novel TCR-T cell therapy. Expediting the pathway to generating meaningful clinical data that their investors need to see is a primary objective of the G-Rex Grant Program. We are happy to see more private sector groups like ImmunoScape leveraging this unique program." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex®. As part of the G-Rex® Grant, ImmunoScape plans to complete their pre-clinical process development including the incorporation of Wilson Wolf's fully closed-system G-Rex® bioreactors. ImmunoScape will also get early access to a new line of GMP cytokines from Bio-Techne that are tailor-made for use with G-Rex. These new offerings, called ProPak™ GMP Cytokines, are designed to streamline reagent preparation and administration in a GMP manufacturing setting. The new products will help companies like ImmunoScape save thousands of dollars per manufacturing run, while simplifying and streamlining processes for reduced variability. Additionally, ImmunoScape's G-Rex Grant will help facilitate the technology transfer of their G-Rex centric manufacturing process to their contract development and manufacturing organization (CDMO) partner. The G-Rex Grant will support training runs and engineering runs that will be used to generate the manufacturing batch records for an IND data package submission to the FDA, slated to occur in 2026. ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About ImmunoScape ImmunoScape is a biotechnology company developing next-generation TCR-T cell therapies for the treatment of solid tumors. By leveraging Deep Immunomics and AI-driven insights, ImmunoScape is focused on identifying TCRs with superior therapeutic potential, selecting the best candidates for clinical development. With multiple programs in the discovery and preclinical stages, the company is performing IND-enabling studies and preparing for the lead program to enter into the clinic and exploring strategic partnerships that align with our mission to bring next-generation TCR-T therapies to more patients. For more information, please visit <a href="https://immunoscape.com/" rel="nofollow">https://immunoscape.com/</a>. About ScaleReady ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 4 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" target="_blank" rel="nofollow">info@scaleready.com</a>. About Wilson Wolf Manufacturing Wilson Wolf (<a href="http://www.wilsonwolf.com" rel="nofollow">www.wilsonwolf.com</a>) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex® centric contract development and manufacturing organization (CDMO) specializing in G-Rex® based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder7460"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape-302250120.html" target="_blank">https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape-302250120.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>BIO-TECHNE ISSUES 2024 CORPORATE SUSTAINABILITY REPORT</title> <link>https://investors.bio-techne.com/news/detail/437/bio-techne-issues-2024-corporate-sustainability-report</link> <pubDate>Wed, 18 Sep 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/437/bio-techne-issues-2024-corporate-sustainability-report</guid> <content:encoded><![CDATA[ <div class="xn-content"> MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate culture and provide the foundation for our approach to continuously improving our corporate sustainability. The updated CSR is available in the <a href="https://www.bio-techne.com/about/corporate-and-social-responsibility" target="_blank" rel="nofollow">Corporate and Social Responsibility</a> section of Bio-Techne's website. "I am proud of the progress the team continues to make positioning Bio-Techne for a sustainable future," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our global team remains committed to enriching the communities we live and work in, while delivering the innovation the scientific community relies on to catalyze advances in science and medicine. These are achieved while functioning at the highest level of governance and operational integrity. This focus enables the team to grow the organization in a responsible manner and deliver the products necessary to develop and advance the next generation of therapeutics, vaccines and diagnostics that improve global healthcare." "This latest CSR includes several noteworthy advancements in our sustainability journey," commented Shane Bohnen, Chief Sustainability Officer, General Counsel and Corporate Secretary. "Specifically, we submitted a letter of commitment to reduce our Scope 1, 2 and 3 greenhouse gas emissions, and our reduction targets will be evaluated by the Science Based Targets Initiative (SBTI) in 2026. We also completed our first EcoVadis sustainability assessment to evaluate our performance in environment, labor and human rights, ethics and sustainable procurement, and earned a Bronze Medal in this inaugural evaluation, putting us in the top 67% of all companies assessed. I am looking forward to sharing the team's continued progress furthering our sustainability initiatives." About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. <a href="https://investors.bio-techne.com/company-information" target="_blank" rel="nofollow">About Bio-Techne Corporation</a> (NASDAQ: TECH) Contact: David Clair, Vice President, Investor Relations <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-441 <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder2680"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/bio-techne-issues-2024-corporate-sustainability-report-302249719.html" target="_blank">https://www.prnewswire.com/news-releases/bio-techne-issues-2024-corporate-sustainability-report-302249719.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> <item> <title>ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics</title> <link>https://investors.bio-techne.com/news/detail/436/scaleready-announces-a-g-rex-grant-has-been-awarded-to-verismo-therapeutics</link> <pubDate>Tue, 17 Sep 2024 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://investors.bio-techne.com/news/detail/436/scaleready-announces-a-g-rex-grant-has-been-awarded-to-verismo-therapeutics</guid> <content:encoded><![CDATA[ <div class="xn-content"> ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to <a href="http://www.verismotherapeutics.com/" target="_blank" rel="nofollow">Verismo Therapeutics</a>, a clinical-stage CAR T company developing the novel KIR-CAR platform technology. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex. The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant support allowing for expeditious optimization of cell manufacturing processes. "We are grateful to have been chosen for the G-Rex Grant at Verismo Therapeutics," stated Raymond Luke, Director of Manufacturing Science and Technology at Verismo Therapeutics. "This funding will help us further optimize our cell therapy manufacturing processes by transitioning our active and future pipeline to G-Rex®, ensuring we can deliver life-saving treatments to patients more efficiently and cost-effectively. We are excited to work with ScaleReady to drive forward innovative solutions in cell therapy production." "We are excited to support Verismo Therapeutics through the G-Rex Grant program. Their commitment to advancing cell and gene therapy aligns perfectly with our mission to provide hope to cancer patients one G-Rex at a time. We look forward to seeing the impactful advancements Verismo Therapeutics will achieve with this grant." said John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of G-Rex. As part of the G-Rex® Grant, Verismo will complete optimization of their G-Rex-based KIR-CAR T process and plans to implement this as a platform manufacturing process. Additionally, Verismo will evaluate a suite of critical reagents from Bio-Techne (R&D Systems) including GMP cytokines. Specifically, Verismo will get early access to a line of new, closed system reagents from Bio-Techne, called ProPakTM GMP Cytokines, that are tailor-made for use with G-Rex. The ProPakTM line of GMP cytokines are estimated to be commercially available by the end of 2024. Verismo Therapeutics is committed to pioneering new therapies and technologies that improve patient outcomes. The G-Rex Grant will play a pivotal role in advancing the company's research and development efforts, ultimately contributing to the broader goal of making innovative treatments accessible to those in need. About the KIR-CAR Platform The KIR-CAR platform is a multi-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging tumor microenvironments. Using NK cell derived KIR and DAP12 split signaling provides a novel combined activation and co-stimulation separate from the usual T cell stimulation pathways. It also enables sustained chimeric receptor expression and improves KIR-CAR T cell long term function. This results in prolonged T cell functional persistence and leads to regression of solid tumors in preclinical models that are resistant to traditional CAR T cell therapies. About Verismo Therapeutics Verismo Therapeutics is a pioneer in multi-chain KIR-CAR technology, with its first assets SynKIR™-110 and SynKIR™-310 currently in Phase 1 clinical trials. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve persistence and efficacy against aggressive tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies. For more information, visit: <a href="http://www.verismotherapeutics.com/" target="_blank" rel="nofollow">www.verismotherapeutics.com</a> About ScaleReady™ ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 4 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact <a href="mailto:info@scaleready.com" target="_blank" rel="nofollow">info@scaleready.com</a>. About Wilson Wolf Manufacturing Corporation Wilson Wolf (<a href="file://10.86.178.52/C%24/Users/Andrew%20Scheffler/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/Q8TN4BQV/www.wilsonwolf.com" target="_blank" rel="nofollow">www.wilsonwolf.com</a>) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit <a href="https://www.bio-techne.com/" target="_blank" rel="nofollow">https://www.bio-techne.com</a> or follow the Company on social media at: <a href="https://www.facebook.com/BioTechne" target="_blank" rel="nofollow">Facebook</a>, <a href="https://www.linkedin.com/company/bio-techne/" target="_blank" rel="nofollow">LinkedIn</a>, <a href="https://twitter.com/biotechne" target="_blank" rel="nofollow">Twitter</a> or <a href="https://www.youtube.com/@Bio-Techne" target="_blank" rel="nofollow">YouTube</a>. Contact: David Clair, Vice President, Investor Relations & Corporate Development <a href="mailto:david.clair@bio-techne.com" target="_blank" rel="nofollow">david.clair@bio-techne.com</a> 612-656-4416 <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder6896"> <a href="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.html" target="_blank" rel="nofollow"><img src="https://mma.prnewswire.com/media/2470019/Bio_Techne_Corporation__logo.jpg" title="BT Logo (PRNewsfoto/Bio-Techne Corporation)" alt="BT Logo (PRNewsfoto/Bio-Techne Corporation)"></a> </div> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder0"> </div> View original content to download multimedia:<a id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-verismo-therapeutics-302249217.html" target="_blank">https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-verismo-therapeutics-302249217.html</a> SOURCE Bio-Techne Corporation </div> ]]></content:encoded> </item> </channel> </rss>